Skip to main content


Resilience Acquires SwiftScale Biologics, a Leader in Cell-Free Protein Synthesis Technology

December 2, 2021

Resilience and Harvard University Announce Five-Year R&D Alliance to Incubate New Technologies, Launch Companies to Advance the Manufacture of Complex Medicines

October 15, 2021

Resilience Joins Forces with Children’s Hospital of Philadelphia to Develop Next-Generation Biomanufacturing Technologies, Create Impactful Therapies

October 12, 2021

Resilience to Manufacture mRNA for Moderna’s COVID-19 Vaccine

September 8, 2021

Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies

July 28, 2021

Resilience Receives USD $164 Million Investment from the Government of Canada to Modernize and Expand Its Ontario Biomanufacturing Site, Improving Pandemic Preparedness

May 18, 2021

Resilience Continues Expansion with Acquisition of Biologics Manufacturing Company Ology Bioservices

April 12, 2021

How an East Bay site may lead a biotech manufacturing revolution

San Francisco Business Times, March 3, 2021

With stars aligned and cash in reserve, Bob Nelsen’s Resilience plans a makeover at 2 new facility additions to its drug manufacturing upstart

Endpoints News, March 2, 2021

Resilience Expands North American Capacity with the Acquisition of Two Premier Biologics Manufacturing Facilities 

March 2, 2021

Fireside Chat with Rahul Signhvi, CEO of Resilience

BIO CEO & Investor – February 16, 2021

Resilience bags Sanofi-Genzyme plant in Boston

BioProcess International – February 15, 2021

Sanofi prepares to transfer Allston plant to a new company, but not its city tax breaks

Boston Globe – February 11, 2021

Raging at the pandemic, a VC raises $800M for a company that aims to transform biotech manufacturing

STAT News – November 23, 2020

Resilience Launches to Change the Future of Medicine through Manufacturing  Innovation

November 23, 2020



[email protected]


Ryan Flinn
[email protected]